Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK565965PMID: 33355728
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 897016-82-9
Drug Levels and Effects
Summary of Use during Lactation
Topical tirbanibulin has not been studied during breastfeeding.
However, after topical administration, serum concentrations are very low and the drug is 88% bound to plasma proteins, so amounts in milk are likely to be very low. If tirbanibulin is required by the mother, it is not a reason to discontinue breastfeeding. Do not apply tirbanibulin to the breast or nipple and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Tirbanibulin
CAS Registry Number
897016-82-9
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities.[Eur J Med Chem. 2011]Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities.Fallah-Tafti A, Foroumadi A, Tiwari R, Shirazi AN, Hangauer DG, Bu Y, Akbarzadeh T, Parang K, Shafiee A. Eur J Med Chem. 2011 Oct; 46(10):4853-8. Epub 2011 Aug 4.
- Review 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.[Ann Pharmacother. 2022]Review 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.Dao DD, Sahni VN, Sahni DR, Balogh EA, Grada A, Feldman SR. Ann Pharmacother. 2022 Apr; 56(4):494-500. Epub 2021 Jul 23.
- SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases.[Front Oncol. 2022]SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases.Omar AM, Khayat MT, Ahmed F, Muhammad YA, Malebari AM, Ibrahim SM, Khan MI, Shah DK, Childers WE, El-Araby ME. Front Oncol. 2022; 12:879457. Epub 2022 May 20.
- Tirbanibulin Attenuates Pulmonary Fibrosis by Modulating Src/STAT3 Signaling.[Front Pharmacol. 2021]Tirbanibulin Attenuates Pulmonary Fibrosis by Modulating Src/STAT3 Signaling.Wang X, Ren R, Xu Z, Huang H, Jiang W, Ma J. Front Pharmacol. 2021; 12:693906. Epub 2021 Jul 19.
- Review Tirbanibulin: First Approval.[Drugs. 2021]Review Tirbanibulin: First Approval.Markham A, Duggan S. Drugs. 2021 Mar; 81(4):509-513.
- Tirbanibulin - Drugs and Lactation Database (LactMed®)Tirbanibulin - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...